Delving into the Latest Updates on Esketamine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(-)-Ketamine, (S)-(−)-ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone

+ [21]

Target

NMDA receptor

Action

antagonists

Mechanism

NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Depressive DisorderMajor depressive disorder, moderate (MDD)Depressive Disorder, Major+ [5]

Inactive Indication

Drug abuseLiver InjuryRhinitis, Allergic+ [1]

Originator Organization

Pfizer Inc.

Active Organization

Yichang Humanwell Pharmaceuticals Co., Ltd.Janssen-Cilag International NVJanssen Research & Development LLC

+ [6]

Inactive Organization

Auris Medical AG

Xian-Janssen Pharmaceutical Ltd.Janssen-Cilag SA

+ [1]

License Organization-

Drug Highest PhaseApproved

First Approval Date

Germany (01 Aug 1997),

Pain

RegulationBreakthrough Therapy (United States), Fast Track (United States), Priority Review (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H17Cl2NO

InChIKeyVCMGMSHEPQENPE-ZOWNYOTGSA-N

CAS Registry33643-47-9

We systematically searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to August 2025 for randomized controlled trials investigating the effect of perioperative esketamine on PONV. The primary outcome was PONV incidence. Secondary outcomes included time to first flatus, postoperative pain degree, anxiety scores, agitation, anesthesia recovery time, and post-anesthesia care unit (PACU) stay duration. Data were analyzed using RevMan 5.4 and STATA 15.0 software. Sensitivity and subgroup analyses were performed to assess result stability and explore potential sources of heterogeneity.

RESULTS:

Thirty-eight randomized trials (3,425 patients) were included. Esketamine reduced the risk of nausea (RR=0.69, 95% CI: 0.53-0.90) and vomiting (RR=0.75, 95% CI: 0.57-0.98), shortened time to first flatus (SMD=-0.81, 95% CI: -1.48 to -0.15), and decreased rescue analgesic needs within 2 days (SMD=0.32, 95% CI: 0.2-0.5). However, it prolonged anesthesia recovery time (SMD=0.97, 95% CI: 0.28-1.67) and PACU stay (SMD=0.76, 95% CI: 0.27-1.26).

CONCLUSIONS:

Perioperative esketamine may reduce PONV and aid gastrointestinal recovery, but its potential to delay anesthesia recovery and PACU discharge requires consideration. Further studies are needed to clarify its risk-benefit profile.

DATE OF FIRST SUBMISSION TO PROSPERO:

10 March 2024.

DATE OF THE START OF STUDY SCREENING AGAINST ELIGIBILITY CRITERIA:

21 March 2024.

31 Dec 2026·ANNALS OF MEDICINE

Effects of nine sedative-analgesic combinations on fatigue after gastrointestinal endoscopy: a randomized controlled 3 × 3 factorial trial protocol

Article

Author: Huang, Lei ; Kuai, Ling-yu ; Liu, Lin-lin ; Gui, Wen-hu ; Lv, Jun ; Peng, Ke ; Ji, Fu-hai ; Xu, Li-na

INTRODUCTION:

Post-procedural fatigue is common after sedated gastrointestinal endoscopy and prolongs recovery. We describe a protocol for a prospective, single-center, randomized, controlled, 3 × 3 factorial trial to evaluate the effects of different sedative-analgesic combinations on patient-reported fatigue after gastrointestinal endoscopy.

PATIENTS AND METHODS:

Three hundred and fifteen patients (aged ≥ 45 years, ASA physical status I or II) presenting for gastrointestinal endoscopy with planned intravenous sedation will be randomly allocated (1:1:1:1:1:1:1:1:1; block sizes 9 and 18) to one of nine equip-sized groups generated by the factorial combination of three sedatives (propofol, ciprofol, remimazolam) with three adjuvant analgesics (sufentanil, esketamine, lidocaine). Sedation will be titrated to Modified Observer's Assessment of Alertness/Sedation scores of 1-2. The primary outcome is the Christensen Fatigue Scale score (range 1-10; higher = worse) 30 min after the procedure. The secondary outcome is the composite incidence of intra-procedural hypotension (mean arterial pressure < 65 mmHg) and hypoxemia (SpO₂ < 90% for ≥ 10 s). Primary analysis will employ two-way factorial ANOVA to test the main effects of sedatives and analgesics on the 30-min fatigue score, with an exploratory interaction analysis.

DISCUSSION:

The results of this trial will provide high-resolution evidence on which sedative or analgesic agent most effectively mitigates early post-endoscopy fatigue, thereby informing patient-centered sedation choices and enhancing recovery.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2500112657; registered on November 18, 2025).

31 Dec 2026·ANNALS OF MEDICINE

Letter to the editor regarding: Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials

Article

Author: Xia, Jia-yi ; Shen, Qi-hong

498

News (Medical) associated with Esketamine Hydrochloride

28 Jul 2026

·www.globenewswire.com

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care deliveryMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. Overseen by Neuronetics’ Chief Medical Officer Geoffrey Grammer, M.D., the nearly 7,000-square-foot facility is the largest Greenbrook center to date and reflects a significant investment in the future of interventional psychiatry, serving as a national blueprint for advanced, patient-centered mental health care delivery. Neuronetics is investing in the future of mental health care through a National Center of Excellence designed to expand access to advanced treatment options, accelerate clinical innovation, and improve patient outcomes. The new facility was intentionally designed to address the growing need for effective in-office treatment solutions for patients living with depression and other psychiatric conditions that are not adequately treated with first-line therapies. “The Rockville Center of Excellence is more than a new facility; it is a blueprint for the future of interventional psychiatry,” said Cory Anderson, Executive Vice President and General Manager of Greenbrook Mental Wellness Centers. “By bringing together clinical innovation, advanced treatment options, and a patient-centered model of care, we are building a scalable approach to delivering interventional psychiatry and positioning Greenbrook to lead the field with the launch of innovative new treatment modalities.” As the largest Greenbrook location, the flagship Rockville facility is designed to support high-volume NeuroStar TMS and SPRAVATO® operations and is REMS-certified, ensuring compliance and readiness for advanced treatment delivery. Geoffrey Grammer, M.D., Chief Medical Officer of Neuronetics and Greenbrook Mental Wellness Centers, provides clinical leadership for the Center of Excellence, drawing on his national expertise in interventional psychiatry and experience leading large multidisciplinary care teams. In addition to his executive responsibilities, Dr. Grammer maintains clinical hours at the center, where he provides direct patient care. “Treatment-resistant depression remains one of the most urgent challenges in mental health care,” said Dr. Geoffrey Grammer. “The Rockville Center of Excellence will serve as Greenbrook’s National Center for Clinical Innovation and Research, providing the clinical infrastructure needed to expand access to advanced interventional treatments, evaluate emerging therapies, and continue improving patient-centered psychiatric care.” The Rockville location offers NeuroStar Advanced Therapy, the leading TMS treatment for major depressive disorder (MDD) in adults and adolescents aged 15 and older, backed by the largest clinical data set of any TMS treatment system for depression. NeuroStar is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder (OCD). The center also offers SPRAVATO (esketamine) Nasal Spray for patients with treatment-resistant depression or MDD with suicidal ideation. As Greenbrook's National Center for Clinical Innovation and Research, the facility will serve as a pilot site for emerging treatment modalities before broader implementation across the network. Its specialized clinical infrastructure also positions Greenbrook to evaluate and, if approved by the U.S. Food and Drug Administration, incorporate emerging psychedelic-class therapies into its model of care. Greenbrook Mental Wellness Centers will host a grand opening celebration for the Rockville Center of Excellence, located at 15001 Shady Grove Road, Suite 220, Rockville, Maryland, featuring a ribbon-cutting ceremony and facility tours. To refer a patient, learn more about treatment options, or find a Greenbrook location near you, please visit GreenbrookTMS.com. For more information about NeuroStar TMS Therapy, please visit NeuroStar.com. About Neuronetics Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Neuronetics Contact:Investors:Mike Vallie or Mark KlausnerICR Healthcare443-213-0499ir@neuronetics.com Media:EvolveMKD646.517.4220NeuroStar@evolvemkd.com ### References1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

Drug Approval

28 Jul 2026

·www.globenewswire.com

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release second quarter 2026 financial and operating results prior to market open on Tuesday, August 11, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7ri4xna9. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Investor Contact:Mike Vallie or Mark KlausnerICR Healthcare443-213-0499ir@neuronetics.com Media Contact:EvolveMKD646-517-4220NeuroStar@evolvemkd.com References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

Financial Statement

24 Jul 2026

·www.biospace.com

Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates

iStock, wildpixel Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals. When Eli Lilly announced its intention to buy psychedelics developer AtaiBeckley for up to $3.8 billion, it was the ultimate validation for the novel drug class. Does that mean psychedelics M&A is about to take off? The answer for one analyst is simple: no. “I don’t view it as floodgates open where all 20 big pharma companies look at psychedelics in a serious manner—it could just be a handful, ultimately,” Jefferies Managing Director Andrew Tsai told BioSpace in an interview on Wednesday . ezstandalone.cmd.push(function () { ezstandalone.showAds(129); }); For starters, “there aren’t that many big pharma players in neuro currently,” Tsai noted. And two of these companies, AbbVie and Otsuka Pharmaceutical, recently struck their own deals for psychedelic compounds. Just last month, Japan-based Otsuka closed a $1.2 billion deal for Transcend Therapeutics and its methylone program TSND-201. Meanwhile, AbbVie picked up Gilgamesh Pharmaceuticals’ lead depression candidate for $1.2 billion last year . While not pharmacologically considered a psychedelic, Johnson & Johnson sells Spravato, an inhaled form of ketamine for treatment-resistant depression (TRD). Beyond a shortage of buyers, Tsai continued, there simply aren’t a lot of psychedelic biotechs to target. “I don’t think there’s that many to pick from,” he said. Psychedelics Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst cautioned, however, that the transaction should not be seen as “supporting a uniform re-rating of every psychedelic developer.” July 20, 2026 · 3 min read · Heather McKenzie Read more Currently, the most likely targets would be late-stage companies Compass Pathways and Definium Therapeutics. Compass “retains the most clinically and regulatorily advanced psychedelic asset,” according to a July 20 note from H.C. Wainwright analysts, referring to the company’s synthetic psilocybin candidate COMP360, which has been validated in two late-stage TRD trials. Compass has started the process of submitting a rolling submission with the FDA for the candidate. Meanwhile, Definium—formerly known as MindMed—recently shared Phase 3 efficacy data for its major depressive disorder candidate that Jefferies deemed “profound.” But the late-stage nature of these companies could actually hinder pharma’s appetite. With no pure psychedelic on the U.S. market yet, there are a lot of logistical questions that still need to be ironed out, Tsai explained. He emphasized that AtaiBeckley’s lead asset, BPL-003, is still three years out, with Phase 3 data expected in early 2029. “I guess it’s just a step-wise thing where maybe Big Pharma first wants to see an approval actually happen,” Tsai said, underscoring the fact that the first psychedelic developer to make it to market will need to establish the initial framework for reimbursement, risk evaluation and mitigation strategy (REMS) and treatment-center models. “Maybe Big Pharma is willing to pay only if they see sales pick up, so it might not be [until] six to nine months later after the launch,” the analyst noted. “Ultimately, it is a sales question for Big Pharma, in my opinion, and so to prove that out in the first few quarters would definitely help reassure [the industry].” Psychedelics Psychedelics surge again as Compass, Definium provide more clinical validation Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up. July 9, 2026 · 5 min read · Gabrielle Masson Read more H.C. Wainwright agreed. While Lilly’s Atai buy legitimatized psychedelics as a genuine franchise opportunity, the analysts wrote to investors on Monday, the deal “should not be interpreted as supporting a uniform re-rating of every psychedelic developer.” Even so, Tsai said he believes all psychedelics makers are currently undervalued. “I’ve dealt with the depression landscape for a long time now—many years—and the class of drugs, the type of efficacy we’re seeing, is disruptive and paradigm shifting,” he said. “When you talk to doctors or psychiatrists specifically, they’re eager to adopt, and they tell me that patients are lining up the door for these psychedelics.” Tsai noted that despite the fact that there are multiple antipsychotics such as selective serotonin reuptake inhibitors (SSRIs) on the market, “The newer antidepressants or antipsychotics still manage to do blockbuster sales.” Because of this, he believes there is a large enough market for numerous psychedelic entrants. “Sure, there are advantages and disadvantages within each, but I don’t really think there’s a winner take all scenario,” he told BioSpace . “I think all of them can win ultimately.”

AcquisitionPhase 3

100 Deals associated with Esketamine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10627	Esketamine Hydrochloride	N01AX14 N06AX27	DB11823

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	China	Janssen-Cilag International NV	17 Apr 2023
Major depressive disorder, moderate (MDD)	Australia	Janssen-Cilag Pty Ltd.	09 Mar 2021
Depressive Disorder, Major	European Union	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Iceland	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Liechtenstein	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Norway	Janssen-Cilag International NV	18 Dec 2019
Anesthesia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	18 Nov 2019
Depressive Disorder, Treatment-Resistant	United States	Janssen Pharmaceuticals, Inc.	05 Mar 2019
Pain	Germany	Pfizer Inc.	01 Aug 1997

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Suicidal Ideation	Phase 3	United States	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Bulgaria	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Estonia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Germany	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Hungary	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Malaysia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Slovakia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Africa	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Korea	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Spain	Janssen Research & Development LLC	09 Jun 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05464979 (CTgov)	Early Phase 1	Critical Illness	80	Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato] (Esketamine Intubation Group)	dqlktsandi(znnilcyddx) = vcouibcylc weuvfixefd (ftvevaofnx, 16) View more	-	21 Jul 2026
				Fentanyl+Midazolam (Conventional Intubation Group)	dqlktsandi(znnilcyddx) = mseivqympe weuvfixefd (ftvevaofnx, 20) View more
NCT04860661 (Pubmed \| Eur J Anaesthesiol)	Not Applicable	Depression, Postpartum	322	Esketamine	usxvgixyvm(aculwqurve) = Several mild central nervous events, such as dizziness (10.98%), hallucination (10.37%) and dissociation (5.49%), were observed during esketamine treatment. accbgedikr (embxorqotr ) View more	Positive	01 Jul 2026
				Saline
NCT04425473 (Pubmed \| Pharmacol Res)	Phase 3	Depressive Disorder	435	Esketamine	kaqvahknmq(jhvdzlbiwh) = nmqilspcfq qehuuxybvc (yclelbjeon )	Positive	01 Jul 2026
				Placebo	kaqvahknmq(jhvdzlbiwh) = cqyrquwxns qehuuxybvc (yclelbjeon )
NCT06062550 (Pubmed \| BMC Anesthesiol)	Phase 4	Pain	312	Esketamine 0.25 mg/ml	mrpycuuefa(lcaudnpzxt) = did not differ among three groups (Esk50 vs. Esk25: mean difference - 2 [95% CI -31 to 28]; Esk75 vs. Esk25: mean difference 13 [95% CI -16 to 43]. qedcroxkyh (guuxojojnr ) View more	Negative	02 Jun 2026
				Esketamine 0.5 mg/ml
NCT02493868 (Pubmed \| Int J Psychiatry Clin Pract)	Phase 3	Psychotic Disorders	5,116	Esketamine	cgqhobjams(rgsttqauor) = krjufabvep znmtpdtkrw (bekgzqhhem )	Negative	12 Feb 2026
				Esketamine	nhxdxcjkzu(bdtxqkcglz) = yaknlelkua uzencynjco (rsxcvmmwfl )
NCT06608030 (Pubmed \| Pharmacol Res)	Phase 4	Depressive Disorder \| Anxiety Disorders	142	Esketamine	balsfmkcgv(voqmefphih) = kjmplkmlbt tmebglrojt (ojzdskcqaq ) View more	Positive	01 Dec 2025
				Saline	balsfmkcgv(voqmefphih) = grxenygomx tmebglrojt (ojzdskcqaq ) View more
NCT07034963 (Pubmed \| Drug Des Devel Ther)	Phase 4	-	30	EsketamineRemifentanil + EsketamineRemifentaniline + EsketamineRemifentanil	hvexvdrnin(dywnlwdfhz) = self-limiting dizziness (66.7%) fnrkkxwdwe (fmvizwgiug ) View more	Positive	01 Dec 2025
NCT05715671 (Pubmed \| Sleep Med)	Not Applicable	Dyssomnias	150	Esketamine loading dose 0.15 mg/kg plus maintenance dose 0.15 mg·kg^-1·h^-1	rfimtybxfx(beqaesknfx) = significantly higher tcoqxzpykr (zvypcxjtzq ) View more	Positive	01 Dec 2025
				Esketamine loading dose 0.3 mg/kg plus maintenance dose 0.3 mg·kg^-1·h^-1
NCT05289050 (Pubmed \| J Pain Res)	Phase 4	-	144	S(+)-ketamine	yugptnejjo(pnimeanagg) = rhgtfjqxby qjzpjfkyen (wjujthslxt, 0.66) View more	Positive	01 Nov 2025
				0.9% sodium chloride solution	yugptnejjo(pnimeanagg) = upzutsdtjj qjzpjfkyen (wjujthslxt, 0.65) View more
NCT04829318 (ESCAPE-LTE, CTgov)	Phase 4	Depressive Disorder, Major	183	Esketamine (Esketamine Nasal Spray + Oral Antidepressant (AD))	eatlsommsm = wtgcrjxxci kfxhckvupd (jlrhxhopfi, ucednbrheg - gfgxffqqho) View more	-	18 Sep 2025
				Esketamine (Esketamine + Oral AD)	gpbivvgxrt(cqztdofomc) = tbigakoern gzguatxgxk (frrnqqolzr, yxgzteqpof - bdscmfsaqh) View more